GSK (GlaxoSmithKline) has announced significant progress in its cancer treatment portfolio, with its drug combinations achieving primary goals in late-stage trials for both ovarian and endometrial cancers. The British pharmaceutical giant reported that its combination of Jemperli and Zejula, when used alongside standard chemotherapy, improved progression-free survival in patients with advanced ovarian cancer. This marks a crucial milestone for GSK as it seeks to expand its oncology offerings.

In a recent trial, the addition of Jemperli to standard chemotherapy and Zejula as a maintenance therapy demonstrated improved survival rates in patients with advanced ovarian cancer, although it did not achieve statistical significance in overall survival as a secondary endpoint. Despite this, GSK remains optimistic about the potential of this combination therapy, particularly in the field of gynecological cancers.

GSK has been actively rebuilding its oncology business, with Jemperli already approved in the US and UK for certain types of endometrial cancer. The company is also preparing for several major drug launches in 2025, including the experimental cancer drug Blenrep.

The company's efforts in cancer treatment have been bolstered by the success of Jemperli and Zejula in treating endometrial cancer. The combination therapy met its primary goal of progression-free survival in a late-stage trial, showing statistically significant and clinically meaningful benefits. This success is particularly noteworthy given the limited treatment options available for patients with mismatch repair proficient/microsatellite stable tumors.

GSK's oncology advancements come at a time when the company is facing challenges in its vaccines business. However, the promising results from its cancer drug trials could provide a much-needed boost to its valuation and market position.